Fig 1: CRISPR/Cas9 screening to identify genes related to MLN8237 sensitivity. A. Schematic illustration for CRISPR/Cas9 screening to identify synergistic kinases with MLN8237 in MDA‐MB‐231 cells. B. The quality control of the CRISPR screening. Principal Component Analysis (PCA) plot was drawn to monitor the distribution and correlation of each group. C. Ranking of the genes whose sgRNAs were depleted in MLN8237‐treated MDA‐MB‐231 cells for 14 days compared with the pretreatment groups. The top three genes on the list are in blue. D. Heatmap of sgRNA enrichment (β scores) in MDA‐MB‐231 cells of the MLN8237 and vehicle treatment groups. Abbreviations: PC1, Principal Component 1; PC2, Principal Component 2; RRA, robust ranking aggregation; GSG2, germ cell‐specific gene 2; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B; NEK1, NIMA related kinase 1; DDR1, discoidin domain receptor tyrosine kinase 1; MINK1, misshapen like kinase 1; AURKB, aurora kinase B; CDK7, cyclin‐dependent kinase 7; TRRAP, transformation/transcription domain associated protein; PRKDC, DNA‐dependent protein kinase catalytic subunit; ATR, ATR serine/threonine kinase; TP53RK, TP53 regulating kinase; EIF2AK4, eukaryotic translation initiation factor 2 alpha kinase 4; TNK1, tyrosine kinase non‐receptor 1; ULK2, Unc‐51 like autophagy activating kinase 2; EPHA10, EPH receptor A10; UHMK1, U2AF homology motif kinase 1; PRKAA1, protein kinase AMP‐activated catalytic subunit alpha 1; MAST4, microtubule‐associated serine/threonine kinase family member 4; CDK10, Cyclin‐Dependent Kinase 10; CSNK1A1, casein kinase 1 alpha 1